Search results | salix pharmaceuticals

Reports

Partnering Agreements with Salix Pharmaceuticals

The Partnering Agreements with Salix Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Partnering Agreements with Salix Pharmaceuticals

The Partnering Agreements with Salix Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Salix Pharmaceuticals and its partnering interests and activities over the past five years.   On demand company reports are prepared upon purchase more »

Insights

Salix Pharmaceuticals: Partnering activity 2009-2014

Salix Pharmaceuticals is a leading specialty pharmaceutical company, listed in the top 50 big biotech list by Current Partnering.

Salix Pharmaceuticals – Getting to grips with gastrointestinal disorders

Specialty Pharmaceuticals Company Salix Pharmaceuticals is committed to providing treatments for a wide spectrum of gastrointestinal disorders.

Salix Pharmaceuticals: M&A activity 2009 – 2014

Salix Pharmaceuticals has announced 3 M&A deals since 2009, with the deals being the acquisition of Santarus, Oceana Therapeutics and the merger between Salix and Cosmo Pharmaceuticals.

M&A news: who will win the bidding race?

M&A news: The Canadian pharma company Valeant Pharmaceuticals is rumoured to be raising money to make a bid for specialty drugmaker Salix Pharmaceuticals, according to Bloomberg, which cites people familiar with the matter.

Merger news : Actavis eyes $3 billion bid for Almirall

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Mylan bids on old drugs of GSK

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs.  

Dealtalk: TPG explores $3 billion sale of specialty drugmaker Aptalis

TPG Capital LP has been exploring a sale of Aptalis Pharma, a specialty drugmaker it has owned since 2008 and values at more than $3 billion, according to dealtalk.

Real M&A: Forest Labs Seen Needing Deal Amid Patent Loss

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire

Dealmakers weekly review – March 19 2012 – GSK, Alcon, Thrombogenics, Omega Pharma, Shire, Ferrokin, Asahi Kasei, Zoll Medical

Deal making on the up in the past week, with major deals announced by GSK, Alcon, Shire and Asahi Kasei

Partnering 2011: Leading deals by upfront payment, another measure of deal value to the licensee

Analysis of date from the leading deals and alliances service Current Agreements, shows that many deals have eye watering headline values, however these deals often require an enormous amount to be successful during the development phases in order for the full value of the deal to be realized

Events

Sorry, your search returned no results.


Deals

Endo makes counter bid for Salix

Endo International has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common stock of Salix Pharmaceuticals

Valeant acquires Salix Pharma for $14.5 billion

Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix

Salix Pharma enters into m&a with Cosmo Pharma

Salix Pharmaceuticals and Cosmo Pharmaceuticals announced a definitive m&a agreement under which Salix will combine with Cosmo Technologies for $2.7 billion.

Salix acquires Santarus for $2.6 billion

Salix Pharmaceuticals acquires specialty pharma, Santarus for a whopping $2.6 billion cash transaction. 

Real M&A: Forest Labs Seen Needing Deal Amid Patent Loss

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif